Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives

Less than a month after rebranding from JDRF to Breakthrough T1D, the leading type 1 diabetes advocacy organization has now released new consensus guidance related to the monitoring of early-stage type 1 diabetes.
Debuted on the final day of the 84th American Diabetes Association Scientific Sessions, the consensus document seeks to fill a gap in guidance around autoantibody-positive individuals in early-stage type 1 diabetes as the community develops new means to delay or prevent progression of the disease. Proof of the document’s significance, it has received endorsement from both the ADA and the European Association for the Study of Diabetes, wi...

At the 84th American Diabetes Association (ADA) Scientific Sessions, INHALE-3 was among the trials to take center stage.
A phase 4 trial comparing the use of inhaled insulin (Afrezza) against standard care, results demonstrated use of inhaled insulin, in addition to insulin degludec, was associated with improved HbA1c in patients with type 1 diabetes, with an improvement of 0.5% or greater observed among 21% of those on inhaled insulin and 5% of those with usual care.
At the meeting, study investigator Grazia Aleppo, MD, professor of Medicine and director of the Diabetes Center at Northwestern University, joined hosts Diana Isaacs, PharmD, and...

Despite being a chronic autoimmune disease, the burden of type 1 diabetes is often overlooked in public health discussions. Not only are patients with type 1 diabetes being tasked with understanding disease pathophysiology as an integral part of optimal management, but also with keeping up with advances in pharmacotherapy and technology.

As a result, patient support programs, such as Blue Circle Health, have emerged to fill a vital role in the management teams for people with diabetes. Provided at no cost to patients through funding from the Helmsley Charitable Trust, the program is designed to free education and support programs...

In this special edition episode from the 84th American Diabetes Association Scientific Sessions, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, are joined by Davida Kruger, NP, a certified nurse practitioner in the Division of Endocrinology at Henry Ford Health System in Detroit.

During the episode, Kruger takes hosts on a deep dive into the latest in diabetes technology at the meeting, with a focus on advancement in automated insulin delivery and continuous glucose monitoring (CGM) technology. In the early half of the episode, Kruger discusses the results of the SECURE-T2D trial, which examined use of the...

On the opening day of the 84th American Diabetes Association Scientific Sessions, the ADA ushered in a new era for their organization with the announcement of the formation of the Obesity Association.
Created more than a decade after the American Medical Association recognized obesity as a disease, the new subdivision of the ADA was created to further the organization’s mission of advocating for and advancing treatment for patients. According to a news release, the ADA intends to develop a Standards of Care for Obesity and to leverage education, advocacy and evidence-based support to reduce barriers to optimal care fo...

In this special edition recorded at the 84th American Diabetes Association Scientific Sessions, Carol Levy, MD, director of the Mount Sinai Diabetes Center and Type 1 Diabetes Clinical Research, joins the podcast for a deep dive into the INHALE-3 trial and how to incorporate individual patient-level factors into the management strategy of patients with type 1 diabetes who could benefit from inhaled insulin (Afrezza).

Their second on-site episode focused on the INHALE-3 trial, hosts Diana Isaacs, PharmD, an endocrine clinical pharmacist, director of Education and Training in Diabetes Technology, and codirector of Endocrine Disorders in Pregnancy at the Cleveland Clinic, a...

This special edition episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives focuses on top highlights and updates in diabetes technology from the 84th American Diabetes Association Scientific Sessions.

In the episode, hosts Omnipod 5 and the SECURE-T2D trial, a study comparing use of simplified meal announcement vs precise carbohydrate counting with the Medtronic MiniMed 780G, and real-world data from Tandem pump users. Later in the episode, hosts discuss their experience on the conference floor getting hands-on interactions with soon to come or recently released diabetes technology showcased at the meeting, including the Sequel Twiist, Abbott’s Libre 3 Plus, an...

In this episode of Diabetes Dialogue: Technology, Therapeutics, & Real-World Perspectives, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, provide a June 2024 update focusing on a trio of topics across the spectrum of diabetes management.

In the episode, hosts discuss the US Food and Drug Administration clearance of 2 new over-the-counter continuous glucose monitoring systems from Abbott, the renaming of JDRF to Breakthrough T1D, and the FDA clearance of the CamAPS FX for people with type 1 diabetes.

Chapters: 
00:00 - Intro
00:40 - Abbott OTC CGM
06:20 - Diabetes Technology Pipeline
10:45 - JDRF Rebrands as Breakthrough T...

In this episode, hosts provide their audience with an overview of a pair of new studies on the topic of diabetes in pregnancy: the GLAM and CRISTAL studies.

To celebrate the FLOW trial and break down what it means for people with type 2 diabetes and CKD, hosts Diana Isaacs, PharmD, and Natalie Bellini, DNP, recorded a special edition episode to discuss the clinical application of this trial, unmet need in CKD management, the future of incretin therapies, and more!

Chapters:
00:00 - Intro 
00:40 - FLOW Background
02:55 - FLOW Results
07:08 - Combination with SGLT2 Inhibitors
12:00 - Future Implications